Shots:
- Carlyle & SK Capital have entered into definitive agreement to acquire Bluebird Bio for $3/share in cash, delisting it from public market. Acquisition will fund Bluebird’s commercial delivery of gene therapies for SCD, β-thalassemia, & cerebral adrenoleukodystrophy, with closing expected in H1’25
- As per the deal, Bluebird stockholders will get $3/share & contingent value right (CVR)/share allowing stockholders to receive additional $6.84/CVR in cash if Bluebird achieves $600M in net sales within 12mos. trailing period ending on Dec 31, 2027
- Bluebird has also amended loan terms with Hercules Capital to secure liquidity for sustaining operations until closing
Ref: Businesswire | Image: Bluebird Bio
Related News:- Carlyle to Acquire Baxter International’s Vantive Kidney Care Segment for $3.8B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
